Zydus Cadila has received final USFDA approval to market oxybutynin chloride tablets in USA. The drug is used to treat overactive bladder and urinary incontinence and will be made available in strengths of 5 mg, 10 mg, 15 mg. It is likely to be manufactured at Moraiya plant in Ahmedabad. The group now has over 120 approvals and so far filed over 300 ANDAs (abbreviated new drug applications) since the commencement of the filing process in 2003-04.
Company Profile : Cadila Healthcare Ltd
Leave a Reply